Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001257 · ClinicalTrials.gov registry record

Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses

A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Terminated
Registry status
169
Enrollment target

NCT00001257: Clinical Trial study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00001257 is a clinical trial that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 169 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001257 was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

TERMINATED
Registry status
169 participants
Enrollment target

Study Summary

This study will investigate the inflammatory response. People with abnormal regulation of inflammation and immune defects often have an exaggerated or depressed inflammatory response that results in poor healing of recurrent infections. This study will measure and compare amounts of inflammatory mediators (chemicals involved in the inflammatory response) in healthy normal volunteers and in patients with abnormal immune responses. Healthy normal volunteers and patients with host defense defects or excessive inflammation, as in vasculitis syndromes, may be eligible for this study. Patients must be between 6 and 65 years of age. Participants will have eight small blisters raised on the forearm using a gentle suction device. The top of the blisters will be removed with scissors and a plastic template will be placed over the blisters. The wells of the template will be filled with a salt solution or a mixture of the subject s serum (fluid part of the blood without cells) and a salt solution. Some blisters may be covered with coverslips a small round piece of very thin sterilized glass before adding the fluid. Blister fluid will be removed from the wells at 3, 5, 8, and 24 hours with a syringe and analyzed for inflammatory mediators. A scab will form over the blisters and fall off in about 2 weeks. Participants will have about 4 tablespoons of blood drawn in order to compare the inflammatory mediators in the blood with those in the blister fluid.

Trial Details

FieldValue
Enrollment Target 169 participants
Start Date 1990-04-24
Est. Completion 2019-08-02

Why NCT00001257 stopped before completion

NCT00001257 is an observational study that tracks outcomes without assigning an intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00001257 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00001257 about?

NCT00001257 is a clinical study titled "Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses". This study will investigate the inflammatory response. People with abnormal regulation of inflammation and immune defects often have an exaggerated or depressed inflammatory response that results in poor healing of recurrent infections. This study will measure and compare amounts of inflammatory med...

What is the current status of trial NCT00001257?

This trial is currently terminated. The enrollment target is 169 participants. The study started on 1990-04-24. Estimated completion is 2019-08-02.

Who is sponsoring clinical trial NCT00001257?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06191484 · 169 participants · NA

    Risk and Resilience to Suicide Following Late-Life Spousal Bereavement

  • NCT02016430 · 170 participants · NA

    Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)

  • NCT02621021 · 170 participants · Phase 2

    A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

  • NCT04094701 · 170 participants · NA

    Hip Arthroscopy Postoperative Opioid Demands

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00001257, the US trial registry maintained by the National Library of Medicine. NCT00001257 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.